CervoMed Inc. (CRVO)
NASDAQ: CRVO
· Real-Time Price · USD
10.18
-0.38 (-3.60%)
At close: May 02, 2025, 3:59 PM
10.02
-1.57%
After-hours: May 02, 2025, 05:55 PM EDT
Company Description
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases.
It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery.
The company is based in Boston, Massachusetts.
CervoMed Inc.
| Country | United States |
| IPO Date | May 23, 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Dr. John J. Alam M.D. |
Contact Details
Address: 20 Park Plaza Boston, Massachusetts United States | |
| Website | https://www.cervomed.com |
Stock Details
| Ticker Symbol | CRVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001053691 |
| CUSIP Number | 15713L109 |
| ISIN Number | US15713L1098 |
| Employer ID | 30-0645032 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John J. Alam M.D. | Co-Founder, Chief Executive Officer, President & Director |
| Dr. Robert J. Cobuzzi Jr., Ph.D. | Chief Operating Officer & Director |
| Dr. Claudia Ordonez M.D. | Senior Vice President of Medical Science |
| Dr. Mark A. De Rosch Ph.D. | SVice President of Regulatory & Government Affairs & Program Management |
| Dr. Sylvie L. Gregoire Pharm.D. | Co-Founder & Director |
| Kelly Blackburn M.H.A. | Executive Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | ARS | Filing |
| Apr 29, 2025 | DEF 14A | Filing |
| Apr 18, 2025 | 8-K | Current Report |
| Apr 07, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 17, 2025 | S-8 | Filing |
| Mar 17, 2025 | 10-K | Annual Report |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |